MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!
-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,
-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.
-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!
-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.
Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!
Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.
The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.
What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!
To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!
According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.
VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.
VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.
VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.
The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.
Some of the most recent exciting developments for VeriTeQ (VTEQ)
(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))
November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.
November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.
October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.
October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants
September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office
August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.
July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.
More interesting information on why now is the time to buy VeriTeQ (VTEQ)
VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital
markets with a goal of a future up-listing”
Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.
In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform
other stocks in it’s sector, now that is essentially a BUY rating!
VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q
Inside Safety Technology in the European Union
Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.
EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.
VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications
Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a
great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better
treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,
thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to
grow VeriTeQ and participate in its long-term success.”
This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:
News 
Market Data 
Discover 
AI
